Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment TrialPhase 3, PEACE-1, STAMPEDE, ARCHES ConferenceESMO 2021 19 November, 2021 09:27
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer Presented ByProf. Antonio Alcaraz, Prof. Noel Clarke TrialPhase 3, ARCHES ConferenceEAU 2019 21 May, 2019 23:59